Related Experiment Video
Updated: Oct 1, 2025
Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
[Retinopathy of Prematurity - Update on Classification, Screening, and Therapy]
Insights
Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness in premature infants. Early screening and treatments like anti-vascular endothelial growth factor (VEGF) therapy significantly reduce vision loss risks.
Area of Science:
- Ophthalmology
- Neonatology
- Pediatrics
Background:
- Retinopathy of prematurity (ROP) is a significant cause of preventable childhood blindness.
- This condition primarily affects prematurely born infants, with risk factors including low gestational age and oxygen therapy.
- Timely ROP screening is crucial for identifying infants needing treatment to prevent severe visual impairment.
Purpose of the Study:
- To review current scientific data and treatment recommendations for retinopathy of prematurity.
- To highlight updates in German ROP screening guidelines and anti-VEGF therapy statements.
- To incorporate the latest International Classification of Retinopathy of Prematurity (ICROP3).
Main Methods:
- Literature review of scientific data on ROP.
- Analysis of current treatment guidelines and recommendations.
- Inclusion of updated German guidelines and ICROP3 classification.
Main Results:
- ROP screening effectively reduces the risk of blindness in premature infants.
- Current treatments include laser coagulation and intravitreal anti-VEGF therapy.
- Updated guidelines and classifications provide a framework for ROP management.
Conclusions:
- Early detection and intervention are key to preventing vision loss from ROP.
- Anti-VEGF therapy represents an important advancement in ROP treatment.
- Adherence to updated screening protocols and classifications is essential for optimal patient outcomes.
Abstract:
Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness. This proliferative retinal vascular disease affects only prematurely born infants. Major risk factors include low gestational age and prolonged postnatal oxygen supplementation. ROP screening allows for timely identification of treatment-requiring infants and thus significantly reduces the risk of severe visual impairment and blindness from ROP. Current treatment options comprise retinal laser coagulation and intravitreal anti-vascular endothelial growth factor (VEGF) therapy. We provide a review of scientific data and current treatment recommendations, with special attention to the updated German guideline on ROP screening, the statement of the German ophthalmological societies on anti-VEGF therapy of ROP, and the new third edition of the International Classification of Retinopathy of Prematurity (ICROP3).
